艾普奈珠单抗(Eptinezumab-JJMR) - 药物靶点：CGRP_在研适应症：偏头痛，丛集性头痛_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Eptinezumab、ALD-403、LU AG09221

+ [1]

靶点

CGRP

作用方式

拮抗剂

作用机制

CGRP拮抗剂(降钙素基因相关肽拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Lundbeck Seattle BioPharmaceuticals, Inc.Lundbeck Australia Pty Ltd.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2020-02-21),

偏头痛

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 156338L

来源: *****

Sequence Code 201708H

来源: *****

关联

41

项与艾普奈珠单抗相关的临床试验

NCT05937152

/ Withdrawn临床2期IIT

CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial

The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).

开始日期2025-01-01

申办/合作机构

Mayo Clinic

NCT06701526

/ Recruiting临床4期

Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).

开始日期2024-12-18

申办/合作机构

H. Lundbeck A/S

NCT06628921

/ Not yet recruitingN/A

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study): a TACHIS Sub-study

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.
The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe_5)

开始日期2024-10-30

申办/合作机构

University of Florence

[+1]

100 项与艾普奈珠单抗相关的临床结果

登录后查看更多信息

100 项与艾普奈珠单抗相关的转化医学

登录后查看更多信息

100 项与艾普奈珠单抗相关的专利（医药）

登录后查看更多信息

212

项与艾普奈珠单抗相关的文献（医药）

2025-03-01·ANNALS OF INTERNAL MEDICINE

Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians

Review

作者: Shekelle, Paul G. ; Cooney, Thomas G. ; Yost, Jennifer ; Cross, J. Thomas ; Tice, Jeffrey A. ; Fitterman, Nick ; Obley, Adam J. ; Owens, Douglas K. ; Miller, Matthew C. ; Qaseem, Amir ; Shamliyan, Tatyana ; Etxeandia-Ikobaltzeta, Itziar ; Harrod, Curtis S. ; Linsky, Amy M. ; Hicks, Lauri A. ; Wilt, Timothy J. ; Crandall, Carolyn J. ; Lewis, Johanna ; Maroto, Michael

DESCRIPTION:

The American College of Physicians (ACP) developed this clinical guideline for clinicians caring for adults with episodic migraine headache (defined as 1 to 14 headache days per month) in outpatient settings.

METHODS:

ACP based these recommendations on systematic reviews of the comparative benefits and harms of pharmacologic treatments to prevent episodic migraine, patients' values and preferences, and economic evidence. ACP evaluated the comparative effectiveness of the following interventions: angiotensin-converting enzyme inhibitors (lisinopril), angiotensin II-receptor blockers (candesartan and telmisartan), antiseizure medications (valproate and topiramate), β-blockers (metoprolol and propranolol), calcitonin gene-related peptide (CGRP) antagonist-gepants (atogepant or rimegepant), CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, or galcanezumab), selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors (fluoxetine and venlafaxine), and a tricyclic antidepressant (amitriptyline). ACP used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to analyze the effects of pharmacologic treatment on the following outcomes: migraine frequency and duration, number of days medication was taken for acute treatment of migraine, frequency of migraine-related emergency department visits, migraine-related disability, quality of life and physical functioning, and discontinuations due to adverse events. In addition, adverse events were captured through U.S. Food and Drug Administration medication labels and eligible studies.

RECOMMENDATIONS:

In this guideline, ACP makes recommendations for clinicians to initiate monotherapy for episodic migraine prevention in nonpregnant adults in the outpatient setting as well as alternative approaches if initial treatments are not tolerated or result in an inadequate response. All 3 ACP recommendations have conditional strength and low-certainty evidence. Clinical considerations provide additional context for physicians and other clinicians.

2025-02-01·HEADACHE

Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review

Review

作者: Romozzi, Marina ; Vigani, Giulia ; Rivi, Veronica ; Raffaelli, Bianca ; Burgalassi, Andrea ; Iannone, Luigi Francesco ; Calabresi, Paolo ; Guerzoni, Simona ; Munafò, Antonio ; De Cesaris, Francesco ; Altamura, Claudia

Abstract:

Antibodies targeting either the calcitonin gene–related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti‐CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect. However, differences in therapeutic targets, structure, and pharmacokinetic characteristics may influence their efficacy and safety differently. Therefore, in patients not achieving a clinically meaningful response with one anti‐CGRP antibody, switching to a different antibody may be a viable option. This review examines the pharmacological characteristics and distinctions among anti‐CGRP mAbs, highlighting their mechanisms of action and pharmacokinetic profiles, along with the clinical observational data of switching. Finally, we summarize suggestions from international guidelines.

2025-01-01·HEADACHE

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial

Article

作者: Ettrup, Anders ; Sperling, Bjørn ; Boserup, Line Pickering ; Gryglas‐Dworak, Anna ; Ranc, Kristina ; Josiassen, Mette Krog ; Schim, Jack ; Ashina, Messoud

Abstract:

Objective:

To evaluate long‐term reductions in acute headache medication (AHM) use with eptinezumab versus placebo in patients with prior preventive migraine treatment failures and medication overuse (MO).

Background:

Preventive migraine treatment is recommended for patients for whom AHMs have failed and for those who are using excessive amounts of AHM. MO may worsen headache and migraine symptoms in people with migraine; it is a risk factor for disease chronification and/or MO headache.

Methods:

DELIVER was a multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled, phase 3b clinical trial that randomized adults with migraine and two to four prior preventive failures to eptinezumab 100 mg, 300 mg, or placebo infusion every 12 weeks; patients initially given placebo received eptinezumab 100 mg or 300 mg in the extension period. MO was defined according to diagnostic criteria for MO headache in the baseline diary reports. This post hoc analysis of the DELIVER study included change from baseline in AHM days/month of use (ergotamines, triptans, simple or combination analgesics, and opioids; total and select class‐specific use) in the MO population.

Results:

A total of 890 patients were included in the total population, and 438/890 (49.2%) had MO at baseline. In both the total population and MO population, eptinezumab resulted in greater reductions in total AHM days/month of use during weeks 1–24 than placebo, with triptans showing the largest reduction among AHM classes. Patients switching from placebo to eptinezumab experienced reductions in AHM days/month similar to that of initial eptinezumab treatment. In the extension population, mean (standard error [SE]) changes from baseline in AHM days/month were −4.6 (0.32; 100 mg) and −4.8 (0.32; 300 mg) across weeks 1–4 in patients who received eptinezumab for the entire treatment period and were −4.8 (0.44; placebo–100 mg) and −5.5 (0.44; placebo–300 mg) across weeks 25–28 in patients who switched from placebo to eptinezumab. Mean (SE) changes from baseline in AHM days/month in the extension MO population were −6.5 (0.59; 100 mg) and −6.6 (0.57; 300 mg) across weeks 1–4 in patients who received eptinezumab for the entire treatment period and were −7.1 (0.81; 100 mg) and −8.0 (0.80; 300 mg) across weeks 25–28 in patients who were switched from placebo to eptinezumab. All treatment arms sustained or further reduced AHM use across 18 months of trial participation. Across weeks 1–4, in patients fulfilling criteria for MO at baseline, 68.0% (102/150) of patients treated with eptinezumab 100 mg and 74.7% (109/146) of patients treated with eptinezumab 300 mg reported AHM use below MO thresholds compared to 43.3% (61/141) of patients receiving placebo. In patients with MO at baseline, the proportion of patients without MO remained above 60.0% for all treatment groups during the extension period.

Conclusions:

Eptinezumab reduced total AHM use more than placebo in patients with prior preventive failures and in patients with MO at baseline; largest reductions were observed for triptans. Robust reductions in AHM use after eptinezumab were sustained or further reduced with up to 18 months of treatment, and most patients no longer met thresholds for MO.

72

项与艾普奈珠单抗相关的新闻（医药）

2024-12-02

·蒲公英Ouryao

最新粤港澳大湾区内地九市临床急需进口港澳药品医疗器械目录

转自：广东省药监局编辑：水晶 12月2日，广东省药监局网省消息，广东省药监局和广东省卫健委发布粤港澳大湾区内地九市临床急需进口港澳药品医疗器械目录（2024年）的通告。《通告》指出，本批目录收录34个上市药品及37个医疗器械。对已列入目录的药械产品，将于2024年12月1日起按照《条例》第九条进行管理。 34个药品：卡那奴单抗、维莫德吉胶囊、盐酸维那卡兰注射液、阿仑珠单抗、罗氟司特片、氨己烯酸薄膜衣片、卡博替尼薄膜衣片、阿培利司薄膜衣片、厄达替尼片、注射用羟钴胺素、布西珠单抗、伊匹木单抗注射液、巴氯芬注射液、艾沙妥昔单抗注射用浓缩液、肾上腺素注射液（预充笔）、莱博雷生片、瑞玛奈珠单抗、硫酸瑞美吉泮口崩片、注射用坦昔妥单抗、二十碳五烯酸乙酯软胶囊、阿扎胞苷片、曲美木单抗、注射用芦比替定、阿司福酶α注射液、阿伏利尤单抗、特泽利尤单抗、磷酸芦可替尼乳膏、罗莫佐单抗、重组人促卵泡素α/促黄体素α注射液、注射用重组人促卵泡素α/促黄体素α、艾普奈珠单抗、伊曲莫德片、依洛硫酸酯酶α注射液、维替索妥尤单抗。根据《广东省粤港澳大湾区内地九市进口港澳药品医疗器械管理条例》（以下简称《条例》）中对急需港澳药械实施目录管理的要求，广东省药品监督管理局、广东省卫生健康委员会经研究决定发布广东省粤港澳大湾区内地九市临床急需港澳药品医疗器械目录（2024年）。本批目录将按《国家药品监督管理局国家卫生健康委员会关于临床急需境外新药审评审批相关事宜的公告》（2018年第79号）发布并符合《条例》要求的港澳已上市药品及《条例》实施前已批准的共71个药品及医疗器械收录。对已列入目录的药械产品，将于2024年12月1日起按照《条例》第九条进行管理。特此通告。附件：1.广东省粤港澳大湾区内地九市临床急需进口港澳药品目录（2024年） 2.广东省粤港澳大湾区内地九市临床急需进口港澳医疗器械目录（2024年）广东省药品监督管理局广东省卫生健康委员会 2024年11月29日

2024-10-24

·GBIHealth

斥资13.3亿！默沙东收购新型肿瘤疗法开发商Modifi Biosciences

药械追踪 No.1 / 礼来阿尔茨海默病疗法多纳单抗在英国获批上市 2024年10月23日，礼来（NYS：LLY）宣布，英国药品和保健产品监管局（MHRA）已授予多纳单抗（donanemab）上市许可，每四周静注一次用于治疗英国符合条件的成年人因阿尔茨海默病引起的轻度认知障碍和轻度痴呆。多纳单抗是继渤健和卫材的阿杜卡单抗（aducanumab）（现已撤市）以及卫材的乐意保（仑卡奈单抗）之后，第三种获得全球批准的抗淀粉样蛋白AD疗法。2024年7月，多纳单抗在美国获批上市，9月在日本获批上市。在中国，礼来公司于2023年10月提交了多纳单抗的上市申请，并于当年11月获得优先审评资格，目前仍在审评中。 ->点击文末阅读原文，解锁完整双语新闻 No.2/ 灵北偏头痛疗法艾普奈珠单抗落地粤港澳大湾区 2024年10月23日，灵北旗下预防性治疗成人偏头痛的创新药物艾普奈珠单抗（Eptinezumab）通过“港澳药械通”正式落地粤港澳大湾区中山大学孙逸仙纪念医院。艾普奈珠单抗已于2020年2月获美国FDA批准，适用于成人偏头痛的预防性治疗，这也是FDA批准的首个也是唯一经静脉注射使用的偏头痛预防性治疗的靶向CGRP的单克隆抗体类药物。2022年11月，艾普奈珠单抗落地海南博鳌乐城先行区。 ->点击文末阅读原文，解锁完整双语新闻企业动态 No.1 / 默沙东斥资13.3亿美元收购新型肿瘤疗法开发商Modifi Biosciences 2024年10月23日，默沙东宣布收购Modifi Biosciences，获得其基于DNA修复缺陷治疗难治肿瘤的临床前分子。此次收购包括3000万美元的预付款和总计13亿美元的潜在分期付款。 Modifi Biosciences成立于2021年，致力于开发通过DNA修饰治疗肿瘤的新型药物。该公司基于从耶鲁大学获得的技术开发了一类新型小分子，针对缺乏关键DNA修复蛋白O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）的肿瘤细胞。 ->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

并购优先审批申请上市

2024-10-14

·EndPoints

Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Danish drugmaker Lundbeck will buy La Jolla, CA-based Longboard Pharmaceuticals for $2.6 billion in cash, the companies said Monday morning, marking the largest biopharma M&A deal since July . Neuroscience-focused Lundbeck will get access to a 5-HT2C superagonist that just entered Phase 3 last month for Dravet syndrome, a severe type of epilepsy found in infancy. The experimental medicine, known as bexicaserin, could also apply to other developmental and epileptic encephalopathies like Lennox-Gastaut syndrome and CDKL5 deficiency disorder, the company has said. Lundbeck projects a launch of bexicaserin in the last quarter of 2028 and global peak sales potential of up to $2 billion. The drugmaker also gets an S1P receptor modulator dubbed LP659 that is in Phase 1 and could be tested in multiple neurological diseases. Lundbeck CEO Charl van Zyl said Longboard will “become a cornerstone in Lundbeck’s neuro-rare franchise.” “Bexicaserin addresses a critical unmet need for patients suffering from rare and severe epilepsies, for which there are very few good treatment options available,” van Zyl said in a statement. Longboard spun out of Arena Pharmaceuticals with $56 million in October 2020. It went public five months later. Pfizer then bought Arena for $6.7 billion in December 2021. The deal comes amid a relatively dull past few months for public biopharma M&A, with many of the recent deals falling below $1.3 billion. There has been no deal of $5 billion or higher yet in 2024. Lundbeck itself has been relatively quiet on the acquisition front since its $1.95 billion Alder BioPharmaceuticals deal in September 2019. That led to a migraine drug approval a few months later for Vyepti . The Longboard deal is slated to close this quarter, and both boards have approved it, the companies said. Longboard will be bought for $60 per share $LBPH . Its share price skyrocketed 50% to $58 in premarket trading.

并购上市批准临床3期临床1期

100 项与艾普奈珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾普奈珠单抗	L01XC	DB14040

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Lundbeck Seattle BioPharmaceuticals, Inc.	2020-02-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
药物引起的头痛	临床3期	美国	H. Lundbeck A/S	2021-02-17
药物引起的头痛	临床3期	格鲁吉亚	H. Lundbeck A/S	2021-02-17
药物引起的头痛	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	格鲁吉亚	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	韩国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国台湾	H. Lundbeck A/S	2021-02-17
丛集性头痛	临床3期	美国	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	日本	H. Lundbeck A/S	2020-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02974153 (PROMISE-2, Pubmed \| J Neurol)	临床3期	偏头痛 \| 头痛	1,072	Eptinezumab	糧壓壓窪鹽鏇築網窪艱(艱鹹積範鏇糧顧顧簾獵) = 衊鹽襯夢積積鹹選鹹觸壓構願鏇壓選獵構廠鹽 (遞簾襯憲壓餘鏇廠窪簾 ) 更多	-	2025-01-01
				Placebo	糧壓壓窪鹽鏇築網窪艱(艱鹹積範鏇糧顧顧簾獵) = 淵願壓廠觸窪襯顧廠鹹壓構願鏇壓選獵構廠鹽 (遞簾襯憲壓餘鏇廠窪簾 ) 更多
NCT04688775 (ALLEVIATE, CTgov)	临床3期	丛集性头痛	231	Eptinezumab (Eptinezumab)	蓋壓糧範遞蓋窪繭鏇膚(鹹廠齋壓醖選艱選鹹淵) = 觸淵構窪鹽醖鏇鏇齋壓糧艱製襯憲糧鹹餘鏇構 (簾壓醖齋築網夢蓋餘淵, 0.93) 更多	-	2024-08-09
				placebo+eptinezumab (Placebo)	蓋壓糧範遞蓋窪繭鏇膚(鹹廠齋壓醖選艱選鹹淵) = 醖簾選製積網窪鏇鹹淵糧艱製襯憲糧鹹餘鏇構 (簾壓醖齋築網夢蓋餘淵, 0.89) 更多
NCT05064397 (CHRONICLE, CTgov)	临床3期	丛集性头痛	131	Eptinezumab	夢餘壓製鬱顧鬱鏇壓襯 = 繭鏇艱範艱夢鹹鑰鹹醖繭窪繭鬱蓋淵網觸積繭 (範衊鹹醖選築鏇艱積顧, 壓選築醖廠壓膚壓淵膚 ~ 醖艱鹹觸鏇齋壓鹹範觸) 更多	-	2024-08-06
NCT05284019 (EVEC, CTgov)	临床4期	偏头痛	32	Onabotulinumtoxin-A (Onabotulinumtoxin-A)	憲獵蓋遞淵獵憲獵壓鹹(鏇築選製顧鏇鑰鏇鹽蓋) = 廠網齋構夢鹹繭築鏇窪襯壓積鹽齋夢築窪鑰獵 (醖觸齋糧蓋淵構衊鏇窪, 顧壓鬱繭遞製網餘餘襯 ~ 艱鹽夢選憲顧糧醖廠鹹) 更多	-	2024-05-29
				Eptinezumab (Eptinezumab)	憲獵蓋遞淵獵憲獵壓鹹(鏇築選製顧鏇鑰鏇鹽蓋) = 衊積選齋夢選醖積蓋壓襯壓積鹽齋夢築窪鑰獵 (醖觸齋糧蓋淵構衊鏇窪, 蓋鏇醖衊膚築遞艱餘壓 ~ 觸廠鏇積醖鬱鹽鹹醖鏇) 更多
AAN2024	N/A	偏头痛	-	Eptinezumab 100 mg	範網願觸餘糧觸鬱網鹹(願鏇願鏇鹽製衊簾積鏇) = 襯鏇鹽選構衊衊製廠醖範鹹構糧範鹹鑰蓋壓餘 (獵網憲繭壓壓製衊範觸 )	-	2024-04-09
				Eptinezumab 300 mg	範網願觸餘糧觸鬱網鹹(願鏇願鏇鹽製衊簾積鏇) = 窪選衊觸壓鏇鹹獵壓齋範鹹構糧範鹹鑰蓋壓餘 (獵網憲繭壓壓製衊範觸 )
REVIEW (AAN2024)	N/A	偏头痛	-	Eptinezumab	鏇選壓觸鹹醖築衊鹹鑰(網鏇壓艱積獵廠製夢鬱) = 襯艱鑰窪廠顧鑰獵蓋網糧鑰夢鬱獵齋鹽醖壓餘 (夢顧鹽顧鹹鑰網觸衊壓 ) 更多	积极	2024-04-09
REVIEW (AAN2024)	N/A	偏头痛	94	Eptinezumab (Patients with psychiatric conditions)	醖糧餘憲築繭糧願襯積(衊艱網壓範廠廠遞選築) = 鬱膚廠觸襯鹹鹹艱觸醖鹽製蓋衊齋壓淵鹹構夢 (廠鬱願蓋夢襯範鬱襯範 ) 更多	积极	2024-04-09
				Eptinezumab (Patients without psychiatric conditions)	醖糧餘憲築繭糧願襯積(衊艱網壓範廠廠遞選築) = 築鬱獵選願鏇餘積築繭鹽製蓋衊齋壓淵鹹構夢 (廠鬱願蓋夢襯範鬱襯範 ) 更多
NCT04418765 (DELIVER, EAN2023)	临床3期	偏头痛	563	Eptinezumab 100mg	選積鏇顧衊餘醖積積糧(願積積鑰鑰簾餘壓鬱艱) = 膚淵艱簾壓淵鏇簾顧襯鑰觸膚衊範顧鏇積繭餘 (鏇醖願壓壓獵餘鏇製繭 ) 更多	积极	2023-06-28
				Placebo	選積鏇顧衊餘醖積積糧(願積積鑰鑰簾餘壓鬱艱) = 網窪壓醖膚鑰鹹獵夢壓鑰觸膚衊範顧鏇積繭餘 (鏇醖願壓壓獵餘鏇製繭 )
NCT04418765 (DELIVER, AAN2023)	临床3期	偏头痛	890	Eptinezumab 100mg	網鏇餘餘鬱窪鹹鹽鑰範(壓範顧壓壓觸夢夢願壓) = 願選鑰餘廠網廠遞膚築夢鹹壓艱製獵齋艱範醖 (糧醖艱膚積鬱簾鑰鹹鏇 )	-	2023-04-25
				Eptinezumab 300mg	網鏇餘餘鬱窪鹹鹽鑰範(壓範顧壓壓觸夢夢願壓) = 顧鏇築顧積夢齋鹽築積夢鹹壓艱製獵齋艱範醖 (糧醖艱膚積鬱簾鑰鹹鏇 )
AAN2023	N/A	-	31	Eptinezumab 100mg	襯製憲繭醖鹽襯膚夢衊(鏇憲窪鏇艱積蓋顧積構) = 77.4% reported that treatment improved disability/function after 6 months of use 製鬱鏇膚鑰壓獵鹹窪鹽 (製鹽蓋鑰鏇範窪淵鹽築 ) 更多	积极	2023-04-25